Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Author： Sartore-Bianchi Andrea  

Publisher： Springer Publishing Company

ISSN： 1776-2596

Source： Targeted Oncology, Vol.5, Iss.1, 2010-03, pp. : 19-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 142-151

Bentham Science Publishers

Access to resources Recommend Favorite

Can we predict the response to epidermal growth factor receptor targeted therapy?

By Manegold Philipp  

Targeted Oncology, Vol. 3, Iss. 2, 2008-04 ,pp. : 87-99

Springer Publishing Company

Access to resources Recommend Favorite

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 101-103

Informa Healthcare

Access to resources Recommend Favorite

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature

By Moroni Mauro  

Targeted Oncology, Vol. 3, Iss. 2, 2008-04 ,pp. : 127-130

Springer Publishing Company

Access to resources Recommend Favorite

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

By Ciardiello F.   Tortora G.  

European Journal of Cancer, Vol. 39, Iss. 10, 2003-07 ,pp. : 1348-1354

Elsevier

Access to resources Recommend Favorite